Eli LillyNYSE: LLY

Eli Lilly and Company (NYSE: LLY) is one of the world's largest pharmaceutical companies, headquartered in Indianapolis, Indiana and founded in 1876, best known for its diabetes, obesity and neuroscience medicines. Lilly entered the psychedelic field in July 2026 by agreeing to acquire AtaiBeckley for up to approximately US$3.8 billion (US$6.75 per share in upfront cash, about US$2.8 billion, plus up to US$2.50 per share in milestone-based contingent value rights). Expected to close in the third quarter of 2026, the deal brings Lilly a late-stage psychedelic and neuroplastogen pipeline led by BPL-003, an intranasal formulation of mebufotenin (5-MeO-DMT) in Phase 3 for treatment-resistant depression, alongside VLS-01 (a DMT oral film) and EMP-01 (an oral (R)-MDMA candidate). It is the largest psychedelic-focused acquisition to date, though Lilly notably avoided the term "psychedelic" in its announcement.